325 related articles for article (PubMed ID: 31229512)
21. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
22. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
23. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
24. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
Lips EH; Mukhtar RA; Yau C; de Ronde JJ; Livasy C; Carey LA; Loo CE; Vrancken-Peeters MJ; Sonke GS; Berry DA; Van't Veer LJ; Esserman LJ; Wesseling J; Rodenhuis S; Shelley Hwang E;
Breast Cancer Res Treat; 2012 Nov; 136(1):35-43. PubMed ID: 22961065
[TBL] [Abstract][Full Text] [Related]
25. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
26. Gene amplification in ductal carcinoma in situ of the breast.
Burkhardt L; Grob TJ; Hermann I; Burandt E; Choschzick M; Jänicke F; Müller V; Bokemeyer C; Simon R; Sauter G; Wilczak W; Lebeau A
Breast Cancer Res Treat; 2010 Oct; 123(3):757-65. PubMed ID: 20033484
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
[TBL] [Abstract][Full Text] [Related]
28. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.
Turashvili G; Bouchal J; Baumforth K; Wei W; Dziechciarkova M; Ehrmann J; Klein J; Fridman E; Skarda J; Srovnal J; Hajduch M; Murray P; Kolar Z
BMC Cancer; 2007 Mar; 7():55. PubMed ID: 17389037
[TBL] [Abstract][Full Text] [Related]
29. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
[TBL] [Abstract][Full Text] [Related]
30. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas.
Frolik D; Caduff R; Varga Z
Histopathology; 2001 Nov; 39(5):503-13. PubMed ID: 11737309
[TBL] [Abstract][Full Text] [Related]
31. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
Courjal F; Cuny M; Simony-Lafontaine J; Louason G; Speiser P; Zeillinger R; Rodriguez C; Theillet C
Cancer Res; 1997 Oct; 57(19):4360-7. PubMed ID: 9331099
[TBL] [Abstract][Full Text] [Related]
32. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
33. Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
Basudan A; Priedigkeit N; Hartmaier RJ; Sokol ES; Bahreini A; Watters RJ; Boisen MM; Bhargava R; Weiss KR; Karsten MM; Denkert C; Blohmer JU; Leone JP; Hamilton RL; Brufsky AM; Elishaev E; Lucas PC; Lee AV; Oesterreich S
Mol Cancer Res; 2019 Feb; 17(2):457-468. PubMed ID: 30355675
[TBL] [Abstract][Full Text] [Related]
34. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
Lien HC; Chen YL; Juang YL; Jeng YM
Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
[TBL] [Abstract][Full Text] [Related]
35. Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma.
Tasdemir N; Ding K; Savariau L; Levine KM; Du T; Elangovan A; Bossart EA; Lee AV; Davidson NE; Oesterreich S
Sci Rep; 2020 Jul; 10(1):11487. PubMed ID: 32661241
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
[TBL] [Abstract][Full Text] [Related]
37. Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells.
Chen F; Ding K; Priedigkeit N; Elangovan A; Levine KM; Carleton N; Savariau L; Atkinson JM; Oesterreich S; Lee AV
Cancer Res; 2021 Jan; 81(2):268-281. PubMed ID: 33148662
[TBL] [Abstract][Full Text] [Related]
38. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
39. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
[TBL] [Abstract][Full Text] [Related]
40. Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma.
Gruel N; Lucchesi C; Raynal V; Rodrigues MJ; Pierron G; Goudefroye R; Cottu P; Reyal F; Sastre-Garau X; Fourquet A; Delattre O; Vincent-Salomon A
Eur J Cancer; 2010 Sep; 46(13):2399-407. PubMed ID: 20570624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
